Journal
CHEMISTRY-A EUROPEAN JOURNAL
Volume 27, Issue 11, Pages 3737-3744Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/chem.202004024
Keywords
bioinorganic; cancer; hetero-bimetallic; iron; ruthenium
Categories
Funding
- University of Leeds
- Henry Ellison Scholarship
- University of Bradford's research development fund
Ask authors/readers for more resources
The new bimetallic ruthenium-iron complexes show strong anti-cancer potential in cytotoxicity experiments, especially in targeting hypoxic tumor regions. Additionally, these complexes demonstrate good potential in damaging DNA and inhibiting bacterial and fungal growth.
The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl beta-diketonate complexes, [(bpy)(2)Ru(Fc-acac)][PF6] (bpy=2,2 '-bipyridine; Fc-acac=functionalized ferrocenyl beta-diketonate ligand) are reported. Alongside clinical platinum drugs, these bimetallic ruthenium-iron complexes have been screened for their cytotoxicity against MIA PaCa-2 (human pancreatic carcinoma), HCT116 p53(+/+) (human colon carcinoma, p53-wild type) and ARPE-19 (human retinal pigment epithelial) cell lines. With the exception of one complex, the library exhibit nanomolar potency against cancerous cell lines, and their relative potencies are up to 40x, 400x and 72x more cytotoxic than cisplatin, carboplatin and oxaliplatin, respectively. Under hypoxic conditions, the complexes remain cytotoxic (sub-micromolar range), highlighting their potential in targeting hypoxic tumor regions. The Comet assay was used to determine their ability to damage DNA, and results show dose dependent damage which correlates well with the cytotoxicity results. Their potential to treat bacterial and fungal strains has been determined, and highlight complexes have selective growth inhibition of up to 87-100 % against Staphylococcus aureus and Candida albicans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available